MAPT and Alzheimer disease: From a molecular, biochemical and pathophysiologic perspective, it is reasonable to hypothesize that, in the very early stages of AD, dysfunctional (reduced) CX3CL1 signalling causes enhanced microglial phagocytosis and hyperphosphorylation of Tau protein [72].